company background image
JNJ logo

Johnson & Johnson NYSE:JNJ Stock Report

Last Price

US$148.75

Market Cap

US$358.0b

7D

2.2%

1Y

-10.1%

Updated

23 Jun, 2024

Data

Company Financials +

JNJ Stock Overview

Researches, develops, manufactures, and sells various products in the healthcare field worldwide.

JNJ fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance4/6
Financial Health6/6
Dividends5/6

Narratives

Beta

Narratives bring a range of perspectives from our community.

Johnson & Johnson Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Johnson & Johnson
Historical stock prices
Current Share PriceUS$148.75
52 Week HighUS$175.97
52 Week LowUS$143.13
Beta0.53
11 Month Change1.21%
3 Month Change-4.17%
1 Year Change-10.11%
33 Year Change-9.41%
5 Year Change6.80%
Change since IPO23,700.04%

Recent News & Updates

There's Reason For Concern Over Johnson & Johnson's (NYSE:JNJ) Price

Jun 10
There's Reason For Concern Over Johnson & Johnson's (NYSE:JNJ) Price

Recent updates

There's Reason For Concern Over Johnson & Johnson's (NYSE:JNJ) Price

Jun 10
There's Reason For Concern Over Johnson & Johnson's (NYSE:JNJ) Price

Johnson & Johnson: Market Will Regret The Overreaction

May 31

Johnson & Johnson: Vital Signs Decent, A Compelling Value Case

May 23

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

May 22
We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors

May 16

Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.24

May 03
Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.24

Johnson & Johnson (NYSE:JNJ) Will Pay A Larger Dividend Than Last Year At $1.24

Apr 19
Johnson & Johnson (NYSE:JNJ) Will Pay A Larger Dividend Than Last Year At $1.24

Johnson & Johnson: Buy This Bargain Before It's Gone

Apr 18

Shareholder Returns

JNJUS PharmaceuticalsUS Market
7D2.2%1.0%0.5%
1Y-10.1%17.5%23.7%

Return vs Industry: JNJ underperformed the US Pharmaceuticals industry which returned 17.5% over the past year.

Return vs Market: JNJ underperformed the US Market which returned 23.7% over the past year.

Price Volatility

Is JNJ's price volatile compared to industry and market?
JNJ volatility
JNJ Average Weekly Movement2.5%
Pharmaceuticals Industry Average Movement9.6%
Market Average Movement5.7%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.8%

Stable Share Price: JNJ has not had significant price volatility in the past 3 months.

Volatility Over Time: JNJ's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1886131,900Joaquin Duatowww.jnj.com

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke.

Johnson & Johnson Fundamentals Summary

How do Johnson & Johnson's earnings and revenue compare to its market cap?
JNJ fundamental statistics
Market capUS$357.99b
Earnings (TTM)US$17.07b
Revenue (TTM)US$85.65b

21.0x

P/E Ratio

4.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JNJ income statement (TTM)
RevenueUS$85.65b
Cost of RevenueUS$26.26b
Gross ProfitUS$59.39b
Other ExpensesUS$42.32b
EarningsUS$17.07b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 17, 2024

Earnings per share (EPS)7.09
Gross Margin69.34%
Net Profit Margin19.93%
Debt/Equity Ratio48.0%

How did JNJ perform over the long term?

See historical performance and comparison

Dividends

3.3%

Current Dividend Yield

69%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.